Abbisko Cayman (HKSE:02256) Receivables Turnover : 0.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Abbisko Cayman's Revenue for the six months ended in Jun. 2024 was HK$535.3 Mil. Abbisko Cayman's average Accounts Receivable for the six months ended in Jun. 2024 was HK$0.0 Mil.

Abbisko Cayman Receivables Turnover Historical Data

The historical data trend for Abbisko Cayman's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Receivables Turnover Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Receivables Turnover	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Abbisko Cayman's Receivables Turnover

For the Biotechnology subindustry, Abbisko Cayman's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbisko Cayman's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Receivables Turnover falls into.

Abbisko Cayman Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Abbisko Cayman's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	20.847	/ (	(0	+	0)	/	1 )
=	20.847	/	0
=	N/A

Abbisko Cayman's Receivables Turnover for the quarter that ended in Jun. 2024 is calculated as

	Receivables Turnover (Q: Jun. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Jun. 2024 ))	/	count )
=	535.336	/ (	(0	+	0)	/	1 )
=	535.336	/	0
=	N/A

Abbisko Cayman (HKSE:02256) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Abbisko Cayman Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

8ZD:Germany

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Executives

Lav Asset Management (hong Kong) Limited	2102 Investment manager
Shi Yi	2201 Interest of corporation controlled by you
Xu Yao-chang	2101 Beneficial owner
Yu Hongping	2501 Other
Chen Zhui	2501 Other
Futu Trustee Limited	2301 Trustee
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Yu Hongping	2501 Other
Morgan Stanley	2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Trident Trust Company (hk) Limited	2301 Trustee
Computershare Hong Kong Trustees Limited	2301 Trustee
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you

Abbisko Cayman Headlines

No Headlines